Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Greil

Showing results (81-90 of 145) with videos related to

Pageof 15
Sort By:
Leukemia Research|January 1, 1989
Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with alpha-2-interferon and deoxycoformycinJ Thaler, H Denz, O Dietze, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 18, 2011
Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safeG Resch, R Schaberl-Moser, P Kier, et al.
Oncogene|February 3, 2015
Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemiaD Kern, G Regl, S W Hofbauer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2001
Quality of life measurement in oncology--a matter of the assessment instrument?B Holzner, G Kemmler, B Sperner-Unterweger, et al.
ESMO Open|August 9, 2021
Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literatureR Heregger, F Huemer, G Hutarew, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 1999
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trialG Krajnik, W Wein, R Greil, et al.
Lung Cancer (Amsterdam, Netherlands)|July 22, 2014
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial)F Kocher, A Pircher, A Mohn-Staudner, et al.
Molecular Immunology|November 1, 1988
Importance of an 85 kDa membrane glycoprotein for a variety of cell-cell interactionsT F Schulz, W Vogetseder, M Mitterer, et al.
The Pharmacogenomics Journal|January 20, 2019
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
British Journal of Cancer|April 14, 2015
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trialF Fitzal, M Filipits, M Rudas, et al.
Pageof 15

Showing results (81-90 of 145) with videos related to

Sort By:
Pageof 15
Leukemia Research|January 1, 1989
Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with alpha-2-interferon and deoxycoformycinJ Thaler, H Denz, O Dietze, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 18, 2011
Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safeG Resch, R Schaberl-Moser, P Kier, et al.
Oncogene|February 3, 2015
Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemiaD Kern, G Regl, S W Hofbauer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2001
Quality of life measurement in oncology--a matter of the assessment instrument?B Holzner, G Kemmler, B Sperner-Unterweger, et al.
ESMO Open|August 9, 2021
Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literatureR Heregger, F Huemer, G Hutarew, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 1999
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trialG Krajnik, W Wein, R Greil, et al.
Lung Cancer (Amsterdam, Netherlands)|July 22, 2014
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial)F Kocher, A Pircher, A Mohn-Staudner, et al.
Molecular Immunology|November 1, 1988
Importance of an 85 kDa membrane glycoprotein for a variety of cell-cell interactionsT F Schulz, W Vogetseder, M Mitterer, et al.
The Pharmacogenomics Journal|January 20, 2019
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
British Journal of Cancer|April 14, 2015
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trialF Fitzal, M Filipits, M Rudas, et al.
Pageof 15